Futura Medical plc, a pharmaceutical company specializing in sexual health products, has announced its total issued share capital as of the date of the announcement is 301,405,950 Ordinary Shares. The company currently holds no shares in treasury, so the total number of voting rights in the company is also 301,405,950. Shareholders can use this figure as the denominator for calculating their interest in the share capital of the company under the FCA's Disclosure and Transparency Rules.
Futura Medical is developing a portfolio of innovative products based on its proprietary transdermal DermaSys® technology. Each formulation is separately patented and tailored for specific indications and applications, with a focus on clinical efficacy, safety, administration, and patient convenience. The products are intended for the prescription and consumer healthcare markets.
One of Futura's key products is MED3000, a topical gel formulation for the treatment of erectile dysfunction (ED). The company has conducted two Phase 3 studies using MED3000, which have demonstrated its effectiveness as a clinically proven treatment for ED with a rapid onset and a favorable benefit-risk profile. MED3000 has received a CE Mark in 2021 and US marketing authorization, positioning it for potential over-the-counter classification.
Another product in Futura's portfolio is Eroxon®, a clinically proven topical treatment for adult men with erectile dysfunction. Eroxon® has received FDA approval in the US, CE marking in Europe, and UKCA marking in the UK. It is marketed under the brand name Eroxon® and is known as MED3000 in regions where regulatory approval or commercial distribution agreements have not yet been achieved.
Futura Medical's development and commercialization strategies aim to maximize product differentiation and value creation while minimizing risk. The company is focused on bringing innovative sexual health products to market to address unmet medical needs.